Several risk factors for Crohn's disease have been identified in recent genome-wide association studies. To advance gene discovery further, we combined data from three studies on Crohn's disease (a total of 3,230 cases and 4,829 controls) and carried out replication in 3,664 independent cases with a mixture of population-based and family-based controls. The results strongly confirm 11 previously reported loci and provide genome-wide significant evidence for 21 additional loci, including the regions containing STAT3, JAK2, ICOSLG, CDKAL1 and ITLN1. The expanded molecular understanding of the basis of this disease offers promise for informed therapeutic development.
Recent genome-wide association studies (GWAS) have identified many common variants associated with complex diseases and have rapidly expanded our knowledge of the genetic architecture of these traits. Progress in Crohn's disease (CD), a common idiopathic inflammatory bowel disease (IBD) with high heritability (l s B20-35), has been especially notable, with recent GWAS publications increasing the number of confirmed associated loci from two to more than ten 1 . The results have identified previously unknown pathogenic mechanisms of IBD and promise to advance fundamentally our understanding of CD biology. These recent discoveries highlight, for instance, the importance of autophagy and innate immunity [2] [3] [4] [5] as determinants of the dysregulated host-bacterial interactions implicated in disease pathogenesis. Furthermore, genetic associations have been shown to be shared between CD and other auto-inflammatory conditions-for example, IL23R variants 6 are also associated with psoriasis 7 and ankylosing spondylitis 8 , and PTPN2 variants with type 1 diabetes 3, 5 . As in other studies of complex diseases, restricted sample sizes have resulted in early CD studies focusing on only the strongest effects, which turn out to explain only a fraction of the heritability of the disease.
We recently published three separate GWA scans for CD in European-derived populations 4, 5, 9 , the details of which are shown in Table 1 . Motivated by the need for larger datasets to improve power to detect loci of modest effect, we carried out a genome-wide metaanalysis from our three CD scans. These analyses, together with a replication study in an equivalently sized independent panel, have enabled us to identify at genome-wide levels of significance 21 new CD susceptibility loci. This brings the number of independent loci conclusively associated with CD to more than 30 and provides unprecedented insight into both CD pathogenesis as well as the general genetic architecture of a multifactorial disease.
RESULTS

Meta-analysis of three genome-wide association scans
The combined GWAS study samples (Table 1 ) consisted of 3,230 CD cases and 4,829 controls, all of European descent. Although the individual scans did identify new risk factors, they were only wellpowered to discover common alleles with odds ratios (ORs) above 1.3 (in the case of the WTCCC) or 1.5 (the smaller two scans) (Fig. 1) . By contrast, the combined sample has 74% power at an OR of 1.2, allowing evaluation of the role of alleles with smaller effect sizes for the first time. As two different genotyping technologies were used in the constituent scans, we used recently developed imputation 10, 11 methods to assess association across all three studies at 635,547 SNPs contained on one or both platforms. A quantile-quantile (Q-Q) plot of the primary meta-statistic (single-SNP Z scores; Fig. 2 ) shows a marked excess of significant associations, well beyond what would be attributable to the modest overall distributional inflation (genomic control l o 1.16). Despite the large sample size, the overall inflation is modest because (i) each group had separately tested for evidence of population stratification, and the meta-analysis used a test that combined the results from each study (rather than mixing the raw data and compromising the case-control matching of each study), and (ii) imputation was done on all samples ignoring case status and, thus, would not introduce artifactual differences between cases and controls 12 .
We focus our attention in this study specifically on the 526 SNPs from 74 distinct genomic loci that were associated with P o 5 Â 10 À5 , which is more than seven times the number of SNPs expected by chance even after correction for the modest overall inflation detected. This threshold for follow-up is not meant to imply that there are no genuine associations among SNPs with less significant association in the meta-analysis, but rather reflects a practical desire to prioritize as many true positives as possible for immediate replication. Eleven associations previously replicated and established at genome-wide significance levels ( Table 2) , including both 'historical' associations at NOD2 (also known as CARD15) 13, 14 and 5q31 (IBD5) 15 as well as recent replicated findings from individual GWA scans [2] [3] [4] [5] [6] 16 such as IL23R, ATG16L1, IRGM, TNFSF15 and PTPN2, were among the 74 regions represented in this tail of the distribution of association statistics. However, even after removal of all SNPs in linkage disequilibrium (LD) with these 11 loci, there continued to be a substantial excess of associated alleles beyond that which would be expected by chance (Fig. 2) .
Replication of 21 newly identified loci
As these 74 regions included the 11 already reported as independently replicated and meeting genome-wide significance thresholds, this replication experiment effectively explored 63 putative associations in previously unreported regions with 11 positive controls (Supplementary Table 1 online). To identify the true risk factors among these 63 regions, we carried out a replication study involving 2,325 additional CD cases and 1,809 controls alongside an independent family-based dataset of 1,339 trios of parents and their affected offspring.
Results (significance levels and ORs) for strongly replicating loci, including all positive controls, are presented in Table 2 . The distribution of Z scores from the 63 putative regions shows a marked departure from the null distribution (Fig. 3) , with 19 new regions showing significant replication (P o 0.0008; a value of 0.05/63 representing a conservative threshold expected to be exceeded only once by chance in 20 such replication experiments). SNPs on chromosome 19p13 (replication P ¼ 0.00347, combined P ¼ 2.12 Â 10 À9 ) and in the MHC (replication P ¼ 0.006, combined P ¼ 5.20 Â 10 À9 ; suspected but not previously conclusively established in CD) did not reach this conservative threshold, but so convincingly satisfy proposed thresholds for genome-wide significance (P o 5 Â 10 À8 ) that we propose these as the twentieth and twenty-first additional CD associated-loci defined here. A further 8 of the 42 remaining loci showed nominal replication ( Table 3) .
It is possible that extreme population substructure in the replication sample could give rise to such a marked excess of hits. Although unlikely, this was directly evaluated by the large family-based component of the replication study. Odds ratio estimates from the TDT analysis of the North American, French and Belgian families alone are consistent with those from the UK and Belgian case-control samples (Tables 2 and 3), with all 21 newly defined loci showing ORs in the same direction of association with the original scan in the familybased component (and nearly half showing greater OR than in the case-control arm). None of the significantly or nominally replicating loci show significant evidence for heterogeneity (across studies or between family-based and population-based arms) when corrected for the number of tests performed. This independent family-based evidence confirms that these alleles constitute true CD-associated loci.
For this newly expanded set of 32 unequivocally associated loci, we assessed whether there was evidence of significant pairwise interactions that could add further to the overall variance in liability explained by this set of loci. We carried out a case-only analysis of the 3,664 cases in the replication study and observed no interactions that withstood a correction for the number of tests performed (Supplementary Table 2 online). Figure 1 Power to detect a genetic effect of various sizes (odds ratio 1.2, 1.3 or 1.5) versus study sample size. Power is reported here as the probability (given a multiplicative model and risk allele frequency of 20%) of P o 5 Â 10 À5 in a scan, which was the value used to define regions for attempting replication in a larger sample set. Vertical dotted lines show the sample sizes for the three constituent scans and the meta-analysis. Relatively large effects are likely to be detected by any of these scans, whereas only the combined analysis is well powered to detect more modest effects.
Deciphering the genetic architecture of CD The contributions of the 32 loci to disease risk were computed using a standard liability threshold model and are displayed as a histogram of individual variances (Fig. 4) . The observations from this variance analysis indicate that many loci were detected for which the current study had low power and that only a minority of the variance in risk is explained by these 32 loci, suggesting that many additional loci remain to be identified. This is reinforced by the additional eight nominal replications (Table 3) , where only two or three would be expected by chance, and by the continued excess of small P values when these 40 total regions are removed (Fig. 2) .
Although we recognize that fine-mapping is required to identify specific causal variants, we carried out a series of analyses to gain some general insight into the CD associations. We first queried HapMap to discover any instances where a nonsynonymous SNP (nsSNP) was correlated (r 2 4 0.5) to the most associated variant discovered in this study. Accepting that HapMap is not a complete catalog of nsSNPs, but Figure 2 A quantile-quantile plot of observed -log 10 P values versus the expectation under the null. Black points represent the complete metaanalysis, with a substantial departure from the null at the tail (values 4 8 are represented along the top of the plot as triangles). Dark blue points show the distribution after removal of 11 previously published loci, demonstrating a still notable excess. Light blue points show the distribution after removal of all 40 loci that replicate at least nominally. In all the cases, the overall distribution is marginally inflated (l GC o 1.16). including four loci where fine mapping has identified coding variants, we found that just 9 of the 32 genome-wide significant associations were correlated with a known nsSNP (Supplementary Table 3 online).
To explore whether any of the associations reflect a cis-acting regulatory effect on a nearby gene, we evaluated genotype-expression correlation using the panel of 400 lymphoblastoid cell lines previously described 17 . From all genes within 250 kb of the LD-based intervals defined in Tables 2 and 3 , we identified five correlations between expression of a nearby gene and a CD-associated variant (LOD 4 2) (Supplementary Table 4 online). This was far in excess of chance (P B0.001) ( Supplementary Fig. 1 online) and suggests that regulatory variation also contributes to the genetic architecture identified.
DISCUSSION
Genome-wide association studies provide a systematic assessment of the contribution of common variation to disease pathogenesis. A limiting factor is often the size of the case-control dataset, and hence the power to detect any but the most strongly associated loci.
Meta-analysis of existing data provides an obvious potential solution.
As Figure 1 shows, our expectation was that the additional power of the combined dataset would result in the identification of a substantially larger number of readily replicating associations than were derived from any of the smaller, constituent datasets. However, the paradigm of exploring common genetic variation with similar effects across studies (in this case all of European descent) needs to be tested before its results can be accepted as valid.
On the validity of the method, our results are substantially reassuring. All 11 previously confirmed CD susceptibility loci were strongly replicated both in the meta-analysis and follow-up experiment. These include the two widely replicated findings from studies published in 2001 (refs. 13-15) as well as all of the compelling findings from individual GWAS ( Table 2) Table 1 )-9 of 9 previously unreported regions with P o 5 Â 10 À7 in the combined scan were replicated convincingly-emphasizing the validity of the meta-analysis results. Further, all 21 of these loci exceed a conservative genome-wide level of significance (P o 5 Â 10 À8 ) by a substantial margin (all but two have P o 5 Â 10 À9 ), and equivalent strength of association was observed in the family-based subset of our replication sample.
In keeping with other regions recently identified as associated with CD, the 21 newly identified loci do not conform to any obvious pattern in terms of gene content. Thus, as shown in Table 2 , some loci (defined by HapMap recombination hotspots flanking the set of correlated, associated variants) contain just a single gene, some contain many genes and others none. Clearly, the first category provides the most immediate clues regarding pathogenic mechanisms. These genes are discussed briefly in Box 1, together with a number of genes that constitute noteworthy candidates from regions with only a handful of transcripts. Included among these are compelling functional candidates such as STAT3, JAK2 and IL12B, whereas others, such as CDKAL1 and PTPN22, highlight potentially intriguing contrasts between genetic susceptibility to CD and other complex disorders (Box 1). Consistent with previous findings from CD and other complex diseases, we did not find any strong evidence of Figure 3 Distribution of observed Z scores from the 63 newly identified regions explored, along with the expected distribution under the null (a standard normal with mean 0 and variance 1). Even when the 21 regions reaching genome-wide significance are set aside, the distribution is highly skewed: four more results exceed a Z of 2 (one would be expected by chance under the null) and none showed a Z of less than -2 (same expectation under the null), suggesting that even more of the regions investigated here are likely to be found to constitute true-positive associations when additional data become available. Mb, but only this largest signal from the region was followed up. More detailed study of the MHC will be required to identify and localize potentially independent signals from this region. 
A R T I C L E S
deviation from the model of multiplicative (random) effects when we tested for gene-gene interactions among the 32 confirmed associations, in spite of the fact that some of these genes seem to affect the same or overlapping pathways. For loci containing multiple genes or no genes, the picture is less well defined. The identified paucity of correlation between associated SNPs and coding variation suggests that these loci in particular may benefit from eQTL (expression quantitative trait locus) analysis. This approach seeks to correlate genotype and expression patterns and takes into account that such functional relationships need not respect the specific boundaries of LD around the association. One of our groups previously reported an eQTL effect implicating PTGER4 at the 5p13 locus 9 . A notable outcome from our present analysis was at the established IBD5 locus 15 , where CD-associated SNPs were associated with decreased SLC22A5 mRNA expression. Although a SNP had previously been proposed as regulating SLC22A5 transcriptional activity 18 , these data suggest for the first time that the most diseaseassociated variants in the IBD5 region, including a coding variant in neighboring SLC22A4, are the same variants most associated with SLC22A5 expression. Further, the most significant CD-associated eQTL reported here affects ORMDL3 (lod score ¼ 20) on chromosome 17, and SNPs in precisely the same region were recently shown to be strongly associated with childhood asthma 19 . This suggests that the same polymorphisms might underlie susceptibility to both CD and asthma, possibly by perturbing ORMDL3 expression.
The new loci that we identified are of modest effect size, which is unsurprising given that all loci with larger impact on disease risk were discovered in the original scans (as might be expected). The small sizes of these effects explains the lack of overlap between linkage results in CD and these newly discovered loci ( Supplementary Fig. 2 online) , with the possible exceptions of combined effects of multiple highranking associations on chromosomes 5q and 6p. Indeed, the linkage evidence that led to the discovery of the IBD5 locus was very likely boosted by the nearby effects at IL12B and IRGM. As expected, the , and for our replication sample to replicate (at Bonferroni corrected P values), a 20% variant explaining a given fraction of variance. Note how quickly this curve moves from nearly zero power to detect tiny effects (less than one tenth of one percent) to nearly full power to detect larger effects (presuming they are well covered by the current generation of GWAS chips). Complete power near the origin would likely reveal a more complete exponential distribution, with many very small effects. These are likely to increase somewhat once the causal variant or variants are identified in each locus. Indeed, NOD2 and IL23R are distant outliers, each explaining 1-2% of total variance, partially because multiple causal variants have already been discovered at these loci 6, 13 . evidence from mouse models of colitis [33] [34] [35] [36] . A recent study 39 reported the induction of autophagy by mutant LRRK2, which is of interest given the strong associations between CD and the autophagy genes ATG16L1
and IRGM 2-5 . The same locus also contains the gene MUC19, which encodes a large protein with multiple serine-and threonine-rich repeats characteristic of the proteins encoded by the mucin gene family. The mucin proteins are core components of the mucus layer, which protects the intestinal epithelium from injury, and mucin deficiency leads to intestinal inflammation in mouse models of colitis 40 .
CDKAL1: the protein encoded by this gene is poorly characterized, but CDKAL1 is noteworthy for being recently confirmed as gene associated with type 2 diabetes susceptibility 24, [41] [42] [43] . In this study, we find that SNPs from the same intron of CDKAL1 that shows association with T2D are associated with CD, but the associated alleles for the two diseases are not correlated with each other.
ICOSLG (inducible T-cell co-stimulator ligand): this co-stimulatory molecule is expressed on intestinal (and other) epithelial cells and may have a role in their antigen presentation to and regulation of mucosal T lymphocytes 44 . Upon maturation, plasmacytoid dendritic cells express ICOSLG and drive the generation of IL-10-producing regulatory T cells 45 .
PTPN2 and PTPN22 (protein tyrosine phosphatase, nonreceptor types 2 and 22):
both of these genes are associated with other autoimmune and inflammatory diseases and the effect described here for PTPN2 is similar to that previously described for type 1 diabetes (T1D) 46 . However, the association of PTPN22 with CD, although mapping to the same coding variant (R602W) that is a risk factor for T1D and rheumatoid arthritis 47, 48 , is in the opposite direction, with the T1D and rheumatoid arthritis risk allele, 602W, offering protection from CD.
ITLN1 (intelectin-1): this gene known to be expressed in human small bowel and colon, and encodes a 120-kDa homotrimeric lectin recognizing galactofuranosyl residues found in cell walls of various microorganisms but not in mammals 49 . Human intelectin-1 is structurally identical to the lactoferrin receptor (LFR), expressed within the enterocyte brush border, and seems critical in membrane stabilization, preventing loss of digestive enzymes and protecting the glycolipid microdomains from pathogens 50 . In addition, intelectin expression is reported in Paneth cells in both mouse and pig small intestine, further pointing to a role in innate immunity.
only gene conclusively discovered via linkage (NOD2) is one of two loci which stand well out from the remainder of the distribution of effect sizes (Fig. 4) . The other outlier, IL23R, illustrates an interesting characteristic of linkage: because (unlike in NOD2) the most penetrant risk allele has very high frequency (93%), it is nearly invisible to linkage analysis despite the high OR; highly protective rare alleles are simply not present in multiplex affected families and thus do not influence allele sharing substantially. Using a liability-threshold model, we estimate that the 32 loci identified to date explain about 10% of the overall variance in disease risk, which may be as much as a fifth of the genetic risk, given previous estimates of CD heritability of approximately 50% (ref. 20) . This observation is consistent with the fact that these loci collectively contribute only a factor of two to sibling relative risk (l s ), and even this figure is dominated by the substantial contribution of NOD2 variants. However, it should be emphasized that the full impact of the new loci cannot be determined until causal variants have been identified by directed sequencing and fine-mapping experiments. Until then, the proportion of the variance in CD risk explained must be measured from the confirmed SNPs, where association is due to LD with causal variants. As multiple causal variants might exist at each locus (ranging in frequency from rare to common), our estimates of variance explained provide only a lower bound for the true contribution of each locus.
In conjunction with results from a very similar gene discovery effort in type 2 diabetes 21 , common lessons are beginning to emerge with respect to the genetic architecture of complex traits. In each example, a substantial increase in sample size achieved through meta-analysis has led to dramatic improvements in gene discovery. In all cases, this progress has revealed an underlying architecture consistent with many individually modest effects, which conventional genetic linkage analysis, and even the largest individual genome-wide association studies, are not well powered to detect. Common variants explaining more than 1% of the genetic variance are rare, whereas well-powered studies have found dozens of variants contributing 0.1% of overall variance in liability. Perhaps surprisingly, neither we nor others have yet to document a substantial role for epistasis among these loci, and a number of associated loci are conclusively mapped to regions with no currently annotated protein-coding genes. Despite the considerable concordant success, a distinct minority of the overall heritability has been explained by these documented associations.
As our study is well powered to identify loci that explain 4 0.2% of the overall variance, but the sum of such loci explains a relatively small fraction of the total, it seems likely that many loci with even more modest effect sizes remain undiscovered. Of particular note is the continued excess of associations outside of the regions studied here, as well as the nominal replication of an additional eight loci, notably greater than expected by chance. Overall, the distribution of Z scores in the replication experiment is clearly skewed toward replication: only 11 of the 63 Z scores in this replication experiment generate Z o 0. If only the 21 strongly confirmed loci were genuinely associated, half of the 42 remaining should end up with Z o 0. Indeed, that 8 of the 42 remaining tests have Z 4 1.5 is itself a highly significant observation (P o 0.0001). Although modest in terms of effect size, identification of such loci is likely to still provide important insights into pathogenic mechanisms, as biological importance need not be proportional to the statistical evidence for genetic association. Closer inspection of regions showing nominal association in the replication experiment reveals that a number of transcripts in these loci are of considerable interest, including CCL2 and CCL7 (ref. 22 ), IL18RAP 23 and GCKR 24 .
It is important to note that the GWAS arrays used for these scans did not offer complete genome coverage of common variation (additional loci may reside in poorly covered intervals) and did not address either rare SNPs or copy number variation effectively. Thus, in spite of the wealth of new susceptibility loci identified by the current study, it seems plausible that there are still more to be found; however, very large datasets are likely to be required to achieve robust statistical support for them. With respect to the present findings, there is much work to be done in resequencing and fine mapping to identify causal variants. Although we do not yet have a complete understanding of the genetic architecture of CD, dramatic progress has now been made toward this goal-and with it, the prospect of directed functional exploration of the pathways identified, insight into how risk alleles interact with environmental modifiers and the hope of new avenues for treatment.
METHODS
Subjects and GWAS. The meta-analysis was based on data from the three genome-wide scans of the NIDDK 4 , WTCCC 5 and Belgian-French 9 studies. Details of the numbers of cases and controls genotyped in the respective scans and of the genotyping platforms used are shown in Table 1 , as are details of the case-control and family cohorts genotyped in the replication study of the metaanalysis. Details of the ascertainment and characterization of these cohorts, as well as of quality control procedures applied to the GWA datasets, were provided in the original scan and replication publications [3] [4] [5] [6] 9 . Recruitment of study subjects was approved by local and national institutional review boards, and informed consent was obtained from all participants.
Imputation. These methods rely on observed haplotype patterns in a set of reference data (the HapMap) and the actual genotype data from each project to make predictions (along with a measure of statistical certainty) at ungenotyped SNPs. We used the program MACH 10 with the NIDDK and Belgian-French data, and IMPUTE 11 with the WTCCC data. Comparisons between the two algorithms yielded very similar results (data not shown). We imputed the superset of polymorphic markers that passed quality control in the original scans 4, 5, 9 . This set was comprised of SNPs on either the Affymetrix 500K only (n ¼ 350,507), Illumina HumanHap300 version 1 only (n ¼ 238,935) or both panels (n ¼ 46,105) such that all association tests done were at least partially based on observed genotype data.
Test for association, effect size estimation and interactions. Using the genotype probabilities (rather than best-guess genotypes) and empirical variances for imputed markers in the case and control tallies, we summarized the standard 1 d.f. allele-based test of association as a Z score within each scan and combined scores across studies to produce a single meta-statistic for each SNP across all three datasets. Odds ratios were estimated separately in TDT samples and each case-control replication collection and then combined and tested for heterogeneity 25 . Interaction tests were done using the case-only epistasis test implemented in PLINK 26 .
Critical regions. Given that most associations contain many correlated SNPs showing signal, we demarcated independent loci by first defining the set of HapMap SNPs with r 2 4 0.5 to the most significantly associated SNP. We then bounded the 'critical region' by the flanking HapMap recombination hotspots that contained this set. These windows very likely contain the causal polymorphisms explaining the associations.
Replication. We defined loci to have been previously confirmed if an earlier study had both detected and replicated the association in independent samples and the association achieved P o 5 Â 10 À8 (recently proposed as an appropriate genome-wide significance level for GWAS 27 ). For replication genotyping, we selected the most significantly associated SNP from each region along with a second, correlated SNP with P o 0.0001 or a second assay on the opposite strand in order to have a technical backup should the first fail genotyping (Supplementary Table 1 ). Replication genotyping for the putatively associated loci was done using primer extension chemistry and mass spectrometric analysis (iPLEX, Sequenom) using Sequenom Genetics Services Institute (UK panel) , and using a custom-made Golden Gate assay on a Beadstation500 (Illumina), following the manufacturer's recommendations (Belgian-French panel). The more completely genotyped SNP of the two from each region was chosen to represent that regional association in analysis (if both were completely typed, the SNP that was more strongly associated in the scan was used). Samples with 410% missing data (n ¼ 267 for Belgian-French data, 111 for the UK data and 8 for the North American data; these samples are not included in the tallies for Table 1) , as well as SNPs with 410% missing data or Hardy-Weinberg P value o0.001, were excluded from this analysis.
Regional annotation via eQTL analysis. The effects of SNPs listed in Tables 2  and 3 on expression of neighboring genes were studied using transcriptome data from the B400 lymphoblastoid cell lines described previously 17 . SNPs that were not genotyped on this panel (n ¼ 14) were replaced with a proxy with r 2 4 0.95 when possible (n ¼ 12). Lod scores 4 2 for genes (probe average) located within 250 kb of the corresponding LD windows were retrieved (see URLs section below). To evaluate the significance of the findings with the CD-associated SNPs, we compared the observed (i) number of genes yielding lod scores 4 2, and (ii) sum of these lod scores, with the corresponding frequency distributions for 1,000 randomly selected sets of 31 SNPs, matched for allele frequency (±0.02) and gene context. Window sizes determined for associated SNPs were used for the matched simulated SNPs.
URLs. mRNA by SNP Browser, http://www.sph.umich.edu/csg/liang/asthma/; meta-analysis test statistics and allele frequencies for all SNPs, http:// www.broad.mit.edu/~jcbarret/ibd-meta/.
Note: Supplementary information is available on the Nature Genetics website.
